Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alexis A. Kordis"'
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91523 (2014)
Nontypeable Haemophilus influenzae (NTHi) is an opportunistic pathogen that is a common cause of acute and recurrent mucosal infections. One uncharacterized NTHi toxin-antitoxin (TA) module, NTHI1912-1913, is a host inhibition of growth (higBA) homol
Externí odkaz:
https://doaj.org/article/42e83e69b89447d78880eaac44e31c1a
Publikováno v:
Journal of Immunological Methods. 393:18-29
Infection with Shigella spp. results in bacillary dysentery and a systemic and mucosal antibody response. The immune response is directed at multiple antigens, including LPS and the invasin plasmid antigen (Ipa) proteins, and is capable of conferring
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb964e278df3bd4de27b1ac5d727af7d
https://doi.org/10.1016/j.jim.2013.04.002
https://doi.org/10.1016/j.jim.2013.04.002
Autor:
M.R. Nelson, Jackie Saunders, K. Ross Turbyfill, Melissa L. Coughlin, Alexis A. Kordis, Ryan T. Ranallo, Theron C. Gilliland, Paul B. Keiser, Chad K. Porter, Robert Gormley, Mark S. Riddle, Chris Soltis, Carlos Williams, David R. Tribble, Joyce Lapa, Edwin V. Oaks, Erica Jones, Robert W. Kaminski, Shahida Baqar
Publikováno v:
Vaccine. 29:7009-7019
Background Shigella flexneri 2a lipopolysaccharide 50 is a nasally delivered subunit vaccine consisting of a macromolecular complex composed of LPS, IpaB, IpaC and IpaD. The current study examined vaccine safety and immunogenicity across a dose range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98dd4c5b6284c93108b35f603a959ef9
https://doi.org/10.1016/j.vaccine.2011.07.033
https://doi.org/10.1016/j.vaccine.2011.07.033
Autor:
Ryan T. Ranallo, Qing Chen, Robert W. Kaminski, Kathleen A. Szabo, Alexis A. Kordis, Malabi M. Venkatesan, Tonia George
Publikováno v:
Infection and Immunity. 78:400-412
The ability of genetically detoxified lipopolysaccharide (LPS) to stimulate adaptive immune responses is an ongoing area of investigation with significant consequences for the development of safe and effective bacterial vaccines and adjuvants. One ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c42ae57bcbbcd23f3fdfa7dd0a83a0f
https://doi.org/10.1128/iai.00533-09
https://doi.org/10.1128/iai.00533-09
Autor:
Riddle MS; Naval Medical Research Center, Silver Spring, MD, USA., Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV
Publikováno v:
Vaccine [Vaccine] 2011 Sep 16; Vol. 29 (40), pp. 7009-19. Date of Electronic Publication: 2011 Jul 23.